Aspire Biopharma Holdings Ratios (2022-2026) | ASBP

Ratios Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
Gross Margin (Quarter) 45.54%-23.47%20.28%
EBT Margin (Quarter) -135,268.16%-189,692.96%-11,367.02%
EBIT Margin (Quarter) -59,015.82%-43,403.52%-5,805.98%
EBITDA Margin (Quarter) -59,015.82%-43,403.52%-5,805.98%
Operating Margin (Quarter) -59,015.82%-43,403.52%-5,805.98%
Net Margin (Quarter) -135,268.16%-189,692.96%-11,367.02%
FCF Margin (Quarter) -56,868.06%-21,775.19%-10,716.76%
Efficiency
Inventory Average (Quarter) 0.14M0.31M
Assets Average (Quarter) 148.40M296.61M297.28M299.01M301.64M161.84M20.23M19.94M20.09M13.53M1.06M1.48M1.70M1.86M4.21M
Invested Capital (Quarter) 0.01M0.22M0.43M4.90M3.62M0.50M0.50M4.74M1.29M0.50M
Leverage & Solvency
Interest Coverage Ratio (Quarter) 9.26-53.66-0.77-0.30-1.03
Debt Ratio (Quarter) 0.000.020.1227.590.250.501.972.130.07
Times Interest Earned (Quarter) 9.26-53.66-0.77-0.30-1.03
Valuation
Enterprise Value (Quarter) -0.62M-0.58M-0.53M-0.50M-0.32M-0.01M-0.05M-0.02M-0.02M-0.00M-1.35M-1.83M
Return Ratios
Return on Sales (Quarter) -13.53%-18.97%-1.14%
Return on Capital Employed (Quarter) 144.56%335.11%-1,901.44%
Return on Assets (Quarter) -0.16%-0.11%-0.11%-0.14%-0.03%